We have shown recently that the T cell stimulatory capacity of DCs pulsed with tumorantigen-derived peptides can be considerably increased by activating the DCs through electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA (TriMix DCs). This vaccine will also be tested in the multicentre trial.

These conjugates were tested in vivo by either direct vaccination or ex vivo DC loading prior to vaccination. Both approaches show similar effectiveness in CTL priming.

This vaccine consists of DC loaded with a single MAA-derived peptide (MAGE-3.A1 or -A2 or Na17.A2). It was tested in a trial in small cohorts of patients (3-9) who were vaccinated with differently composed DC-vaccines.

The protein vaccines were injected combined with a combination of iNKT cell-agonist alpha-GalCer and MPL, a detoxified version of LPS that signals through TLR4. This combination treatment stimulates antigen-specific T and B cell responses that are greater than those elicited with alpha-GalCer or MPL alone.

This vaccine consists of G4-DC loaded with 8 different peptides. It was tested in a trial in small cohorts of patients (3-9) who were vaccinated with differently composed DC-vaccines.

The vaccine for ovarian carcinoma is composed by autologous DCs pulsed with apoptotic autologous ovarian carcinoma cells. Apoptosis is induced by UV.

Melanoma patients were vaccinated with peptides (MAGE-A3, gp100, NA17 and tyrosinase), with and without montanide as adjuvant. No response was observed when vaccinating without the adjuvant. We conclude that Montanide had a clear adjuvant effect for the CD8 T cell responses measured against these four peptides.

This vaccine is composed of DC pulsed with 2 to 3 MAA-derived peptides (combinations of MAGE-3.A2, MAGE-C2.A2 or Na17.A2). It was tested in a trial in small cohorts of patients (3-9) who were vaccinated with differently composed DC-vaccines.

ImmunoVexHSV2 is a product for the prevention of infectious disease, it is a vaccine for genital herpes. In preclinical studies, ImmunoVex HSV2 completely prevents disease and invokes a powerful immune response.

We have worked to strengthen vaccine developments with an improved humanized mouse model. We focus on recombinant vaccines against HIV driven by a powerful poxvirus vaccine system termed MVA BN. To improve our understanding MVA BN has been analyzed thoroughly on the nucleotide level, safety in cell cultures, immune deficient mice as well as in healthy, HIV–infected and other immune deficient humans.

This vaccine was used for RCC patients who were deficient in T cell IFN-gamma and IL-2 production pre-vaccination.

This DC vaccine was produced from the Leukapheresis product, after elutriation, of a metastatic lesion of stage III/IV melanoma patients.

This DC vaccine was produced from matured DC (matured using TNF alpha, IFN alpha and PGE2) which were subsequently transfected with CD40L-encoding RNA and tumor RNA.

Autologous dendritic cells are loaded with apoptotic leukemic cells from patients with B-CLL to be used as vaccine in patients with chronic lymphocytic leukemia. Preliminary data from a clinical study indicate reduction of circulating tumor cells. No adverse effects have been observed.

Three patients were enrolled in a clinical trial and DC vaccine was produced. The DC vaccine was administered into irradiated tumours in RCC of one patient only due to cancer progression in the other two patients. The patient treated is in complete remission 6 months after treatment.

DC based vaccines expressing the tumor antigens PSA or Her2/neu were produced in a pre-clinical work.

CLL-DCV01 is used for multiple injections in patients with previously treated B-cell Chronic Lymphocytic Leukemia.

Manufacturing of cGMP RNA to be used as an API (active pharmaceutical ingredient) in the planned Tri-Mix DC RNA Trial will be performed after obtaining the manufacturing license for RNA loaded DCs.

These dendritic cells were generated from adherent peripheral blood monocytes, subject to quality controls, and subsequently used for intradermal administration in HLA-A1 and HLA-A2 positive patients with stage III/IV melanoma (V administrations with eventual additional ones depending on clinical outcome).

The autologous, apoptotic, leukemic cells (Apo-DC) vaccine was given to 2 cohorts of patients: without additional adjuvants and with GM-CSF as an adjuvant. These two cohorts were monitored for 52 weeks. The clinical and immune monitoring data is being currently analyzed.